Goldman Small Cap Research rates NewCardio (NWCI:OB) a speculative buy Print E-mail
By BioMedReports.Com   
Tuesday, 09 February 2010 07:50


Goldman Small Cap Research share some interesting insights as they initiate coverage of NewCardio (NWCI:OB) with a Speculative Buy recommendation. In his report, analyst Rob Goldman cites several factors for his $4.00 price target.

“With a combined $5 billion annual market for the Company’s first three solutions, NewCardio is well-positioned to capture maket share in the cardiac safety, urgent care and chronic care markets. The Company is led by a first-class management team with a history of success. Now, with NewCardio, they have launched a blockbuster technology platform. As investors become more familiar with the NewCardio story, and management continues to execute, the stock could reach $4.00, said Goldman..”

NewCardio's offerings are used to determine the cardiac toxicity of new drugs in clinical trials and development, and to evaluate cardiac status during acute and chronic patient management. NewCardio's unique 3D ECG approach enables faster, more accurate and less expensive assessment of cardiac status than products/services currently in use, and can provide diagnosis of previously difficult or undiagnosable conditions.

According to Goldman, “NewCardio recently began marketing marketing its flagship cardiac safety product QTinno™, and it has already signed several Master Service Agreements, with more likely in the offing.”


A free copy of the report is available at the Company’s website,

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while performance maybe tracked separately, the same coverage criteria is utilized in determining coverage of all stocks in both research formats.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report’s full disclosures and analyst background fund on our website before investing. To download our research or for more information, visit


NewCardio, Inc. NewCardio is a cardiac diagnostic and services company developing and marketing proprietary software platform technologies to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development. For more information, visit

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus